Lexston Life Sciences Corp. (LEXT) AI Stock Analysis

• Market Cap: C$2.51M
• Dividend Yield: N/A
• Average Volume (3M): 40.70K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.00
• Revenue Growth: N/A
• EPS Growth: 28.37%
• Country: CA
• Employees: N/A
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Industrial Materials
• EPS (TTM): N/A
• Shares Outstanding: 14,793,304
• 10 Day Avg. Volume: 77,591
• 30 Day Avg. Volume: 40,703
• PEG Ratio: -0.01
• Price to Book (P/B): 13.45
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 33 Underperform
• Price Target: ―

The company's stock is rated low due to significant financial challenges, including no revenue and consistent losses. Technical analysis suggests bearish momentum, and the valuation remains unattractive with a negative P/E ratio. While the recent private placement provides some liquidity, it may not be sufficient to address broader financial instability.

Lexston Life Sciences Corp. Business Overview & Revenue Model

Company Description

Lexston Life Sciences Corp. operates as a biotechnology company that provides cannabis testing and research services in Canada. The company also offers analytical testing for cannabis, pathogens, and toxins. In addition, it focuses on developing and validating methods for standardized manufacturing of plant derived psychedelics in the field of mental health and wellness. The company is based in Vancouver, Canada.

How the Company Makes Money

Lexston Life Sciences Corp. generates revenue through multiple streams, primarily focusing on the commercialization of its proprietary biotechnology products and services. The company earns money by licensing its technology to pharmaceutical companies and research institutions. Additionally, Lexston Life Sciences may engage in collaborative research and development partnerships, which provide both funding and shared intellectual property rights. The company also offers diagnostic testing services, which contribute to its earnings. Strategic partnerships and government grants may also play a role in supporting the company's financial growth.

Lexston Life Sciences Corp. Financial Statement Overview

Summary

Lexston Life Sciences Corp. is facing significant financial challenges typical of early-stage biotechnology firms. The lack of revenue and consistent losses signal high operational and financial risks. While the balance sheet shows low leverage, the declining equity and liquidity issues suggest the need for strategic changes or additional funding to achieve sustainability.

Income Statement

The company reported no revenue in the TTM period, indicative of its early stage or developmental phase typical in biotechnology. Net income has consistently been negative, reflecting ongoing losses. Gross profit margin, net profit margin, EBIT margin, and EBITDA margin calculations are not feasible due to zero revenue, indicating operational inefficiencies and financial instability.

Balance Sheet

The balance sheet shows a relatively high equity ratio, with a debt-to-equity ratio of 0.12, suggesting a conservative financing structure. However, the declining trend in total assets and stockholders' equity over recent periods raises concerns about financial sustainability. The return on equity is negative, aligning with the company's unprofitable status.

Cash Flow

Operating cash flow and free cash flow have been consistently negative, highlighting liquidity challenges. The free cash flow growth rate is negative, indicating deteriorating cash-generating ability. The company relies on financing activities to cover cash shortfalls, which may not be sustainable long-term.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	361.01K	149.11K
Gross Profit	0.00	0.00	-26.39K	-29.80K	241.49K	60.10K
EBITDA	-1.54M	-1.54M	-648.32K	-841.73K	-2.29M	-479.82K
Net Income	-1.62M	-1.62M	-867.71K	-1.11M	-2.32M	-876.13K
Balance Sheet
Total Assets	279.49K	279.49K	750.95K	814.30K	952.80K	1.10M
Cash, Cash Equivalents and Short-Term Investments	2.32K	2.32K	390.40K	511.00K	590.49K	949.17K
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	208.82K	208.82K	39.87K	11.21K	79.09K	38.81K
Stockholders Equity	70.67K	70.67K	711.08K	803.10K	873.71K	1.06M
Cash Flow
Free Cash Flow	-1.19M	-1.19M	-723.16K	-987.74K	-1.40M	-608.63K
Operating Cash Flow	-1.19M	-1.19M	-523.18K	-987.74K	-1.40M	-483.16K
Investing Cash Flow	-10.00K	-10.00K	-199.99K	0.00	-109.97K	812.32K
Financing Cash Flow	814.66K	814.66K	602.57K	908.24K	1.15M	620.01K

Lexston Life Sciences Corp. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.21
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LEXT, the sentiment is Positive. The current price of 0.21 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.17, and above the 200-day MA of 0.21, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 65.33 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:LEXT.

Lexston Life Sciences Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
MOOD	42 Neutral	C$1.78M	―	-32.09%	―	-55.18%	78.53%
ENBI	36 Underperform	$1.04M	―	-107.76%	―	―	34.22%
LEXT	33 Underperform	C$2.51M	―	-293.33%	―	―	28.37%

Lexston Life Sciences Corp. Corporate Events

Lexston Mining Corporation Secures $196,000 in Private Placement

Lexston Mining Corporation announced the successful closure of a non-brokered private placement, raising $196,000 through the issuance of 2,450,000 units. These funds will be used for general working capital, and the securities issued are subject to a four-month hold period. This move indicates Lexston’s ongoing efforts to bolster its financial position and support its mineral exploration projects in Canada.

Lexston Mining Corporation Launches Private Placement for Strategic Growth

Lexston Mining Corporation has announced a non-brokered private placement to raise up to $196,000 through the sale of 2,450,000 units priced at $0.08 each. The proceeds will be used for general working capital, with the issuance subject to Canadian Securities Exchange filing requirements and a four-month statutory hold period. This move could potentially strengthen Lexston’s financial position and support its ongoing mineral exploration projects, reinforcing its market presence.